What is an “Orange Book” Annual Report (Form 43) and what does “Annual 43” mean?
In the FDA’s Drug Price Competition and Patent Term Restoration Act system (commonly called the “Orange Book”), companies submit patent and exclusivity information that is tied to applications for drugs. “Annual 43” usually refers to the annual patent-listing update process connected to Form 43 (often described informally as “Annual Report Form 43” or “Orange Book annual 43 submissions”). These updates are used to keep the Orange Book’s listed patents and related information current for a listed drug product.
Because “Annual 43” can be referenced in different ways in different contexts (for example, whether someone is talking about a specific year’s submission vs. a particular drug’s annual update), the exact meaning depends on which product, sponsor, or calendar year you mean.
Where can I find the Orange Book Form 43 submissions, and how do I search for them?
The Orange Book itself is searchable by active ingredient, sponsor, product, and application number. When you find the listed drug, you can typically view the listed patents and related submission history fields that reflect annual updates and changes.
If you tell me the active ingredient (or the NDA/BLA/application number) and the year, I can help interpret what the “Annual 43” entry is showing for that specific product.
Why do Form 43 / annual Orange Book updates matter (especially for generics)?
Annual updates can affect what patents are listed as relevant to a drug at a given point in time. That matters because:
- Generic manufacturers use Orange Book patent listings when preparing certifications for ANDAs (the usual pathway for generic entry).
- Patent listings can influence whether FDA requires a particular type of patent certification and how litigation is triggered or referenced under the Hatch-Waxman framework.
So an “Annual 43” update can change the Orange Book record even if the drug is unchanged clinically.
Does “Orange Book annual 43” always mean a patent change?
Not always. Annual 43-type updates can reflect patent listing maintenance, additions, or corrections, but the visible effect depends on what was actually updated for that product in that year. That’s why the drug identifier (NDA/BLA or product name) is key.
If you’re trying to figure out a specific drug’s patent status, what do you need to provide?
To answer precisely (for example, “what patents were added/updated in the Orange Book annual 43 filing for this product?”), share:
- the drug name (active ingredient + brand, if you know it), and
- either the NDA number or the application number shown in the Orange Book, and
- the year (or the exact “Annual 43” reference you’re looking at).
DrugPatentWatch.com angle (useful if you’re looking for patent timelines)
If your real goal is understanding what patents are listed, when they expire, or what might block generic entry, DrugPatentWatch.com is commonly used for aggregating patent and exclusivity information around FDA-listed drugs. You can use it to cross-check Orange Book listings and track related events. If you share the drug name, I can point you to the most relevant page on DrugPatentWatch.com.
Sources:
[1] https://www.drugpatentwatch.com/